Page 100 - AN-2-2

Advanced Neurology Inflammatory myopathies during COVID-19

autoantibodies, the frequent occurrence of inflammatory a COVID-19-affected patient . Between July 1, 2021, and
[7]
cell infiltrates with a high frequency of T-cells in muscle January 1, 2022, 2240 patients attended the neurology unit
tissue indicates that these are autoimmune illnesses. at Basrah Teaching Hospital, neurophysiology outpatient
Additional organs are commonly affected, including the clinics at Al-Sadr Teaching Hospital, and Basrah Specialized
skin in DM and the lungs, heart, joints, and gastrointestinal Children’s Hospital were analyzed.
tract in both PM and DM, demonstrating that these are The participants were separated into two groups.
systemic autoimmune illnesses. The most commonly The first group (1344) consists of patients who had a
accessible enzymatic assays for verifying skeletal muscle confirmed COVID-19 infection in the previous year and
involvement are serum level measurements for creatine were diagnosed using the European Center for Disease
phosphokinase (CPK), lactate dehydrogenase, aspartate Prevention and Control (ECDC)’s criteria, including a
transaminase, and alanine transaminase . Certain EMG positive polymerase chain reaction (PCR) and/or chest
[4]
alterations, including the size, shape, and recruitment computed tomography (CT) demonstrating bilateral
pattern of the motor unit’s potential, may distinguish peripheral ground-glass opacities in the presence of strong
between necrosis and denervation; however, no EMG clinical, serological, or epidemiological suspicion . The
[8]
abnormalities are specific to myositis . second group of 896 individuals comprises those who have
[4]
In COVID-19-infected individuals, myalgia and an never been infected with COVID-19.
asymptomatic CPK increase are common, but they do 2.2. Method
not correlate with clinical, electrodiagnostic, or histologic
markers of muscle damage, nor with the severity of the A consultant neurologist did a comprehensive history
underlying infection, nor do they predict the start of taking with medical and neurological tests, and a full
myopathy. Myopathy has been described as a clinical evaluation of the patient’s history during the period of
and laboratory diagnosis in 0.5% to 3.1% of COVID- COVID-19 infection was undertaken. A specialized
19 patients . neurophysiologist conducted a thorough electrodiagnostic
[5]
examination consisting of nerve conduction studies and
Myositis as a complication of COVID-19 has been needle electromyography to detect the presence or absence
documented in increasing studies. Individuals with of the features suggestive of inflammatory myopathies,
proximal myopathy, significant bulbar involvement, including normal motor nerve conduction studies in most
and DM-like symptoms, including amyopathic DM and cases (especially if it involved the proximal muscles only)
interstitial lung disease, were included. In the majority and normal sensory nerve conduction studies in all of the
of cases, myositis was identified based on clinical cases. In the needle EMG, the motor unit action potentials
presentation and laboratory findings (e.g., CPK elevation (MUAPs) become short in duration, small in amplitude,
and, where available, myositis-specific autoantibodies) and polyphasic with early recruitment of the MUAPs.
within the context of a molecular diagnosis of a viral Denervating features in the form of spontaneous activity
(e.g., SARS-CoV-2) infection. In a small percentage of (fibrillations and positive sharp waves) might be recorded
instances, muscle biopsies and/or muscle MRIs confirmed in cases of inflammatory myopathies .
[9]
the diagnosis. Electron microscopy ruled out direct viral
invasions as the pathophysiological cause of muscle 2.3. Inclusion criteria
harm in one instance. After muscle injury, inflammation, The survey was carried out on all patients who attended
and compartment syndrome, severe limb ischemia was the three above-mentioned centers during the 6-month
associated with COVID-19-induced hypercoagulation . period. The inclusion criteria for participant eligibility
[6]
The present study aims to estimate the burden of include:
inflammatory myopathies after COVID-19 depending on (i) All patients aged over 18 years of both genders.
clinical and electrophysiological diagnosis; additionally, it (ii) Whether or not they were diagnosed with COVID-19
aims to describe the characteristics of myositis related to infection in the past year. The COVID-19 diagnosis is
COVID-19. based on the previous history of COVID-19 that was
diagnosed according to the COVID-19 case definition
2. Materials and methods from the criteria of the ECDC, which defines the
following categories:
2.1. Participants
• Confirmed case of COVID-19: The diagnosis of
In Basra, a multicentric, analytical, and cross-sectional COVID-19 is made by either a positive PCR or a
survey was carried out to examine nerve conduction serological test (positive immunoglobulin “IgM”
studies (NCS) and electromyographic (EMG) data from or “IgG” or viral antigen).

Volume 2 Issue 2 (2023) 2 https://doi.org/10.36922/an.378